

Ticker: **PFE.US.EQUITY****Pfizer Inc (New York: PFE, Currency: USD)**

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Website: www.pfizer.com
 Number of Employees: 81,000
 Ticker: PFE US

66 Hudson Blvd East New York, NY 10001 United States
 Phone : 1-212-733-2323
 Fax : 1-212-573-7851

 **25.38**

+0.06 (0.24%)


Pfizer Inc. opera como una empresa farmacéutica. Ofrece medicamentos, vacunas, dispositivos médicos y productos sanitarios de consumo para los sectores de oncología, inflamación, cardiovascular y otros de terapia. Atiende a clientes en todo el mundo.

Stock Quote & Chart (Currency: USD)

Last (delayed quote)	25.38	Market Cap (MM)	144,294.6
Open	25.35	Shares Out. (MM)	5,685.4
Previous Close	25.32	Float %	99.3%
Change	0.28	Shares sold short (MM)	106,732,210.0
Change %	1.12	Dividend Yield %	6.7
Day High/Day Low	25.5 / 25.2	Diluted EPS Excl. XO	
52 Wk High/52 Wk low	31.5 / 20.9	P / Diluted EPS Before XO	
Volume (MM)	27.10	Beta	0.53
Avg. Vol - 3 mo (MM)	47.15		

Financial Information (Currency: USD, in mm)

Revenue - LTM	62,463.0	Cash & ST Invest.	20,477
EBIT - LTM	12,048.0	Total Assets	213,396.0
EBITDA - LTM	18,943.0	Total Debt	66,993.0
Net Income - LTM	7,883.0	Total Liabilities	124,899.0
Total Enterprise Value	189,386	Total Equity	88,497.0
TEV/ Total Revenue	3.0 x	Cash from Operations - LTM	13,989.0
TEV/ EBITDA	9.9 x	Cash From Investing - LTM	4,194.0
		Cash from Financing -LTM	-17,481.0

**Company Notes**

2015 Q3	
GAAP Net Income Includes: (in millions, pre-tax)	2014 Q1
A loss of \$470.000 from Asset Write Down	GAAP Net Income Includes: (in millions, pre-tax)
A loss of \$529.000 from Restructuring	A loss of \$140 from Restructuring
A loss of \$163.000 from Impairment of Intangibles	A loss of \$694 from Legal Expense
A loss of \$124.000 from Merger & Acquisition.	A loss of \$139 from Impairments and M & A Expense
A gain of \$35.000 from Disposal of assets.	A gain of \$210 from Asset Disposal. Derivatives. and other
A loss of 92.000 from various one time items.	
2015 Q2	
GAAP Net Income Includes: (in millions, pre-tax)	2013 A1
A loss of \$304.000 from Other One Time Items	GAAP Net Income Includes: (in millions, pre-tax)
A loss of \$25.000 from Asset Write Down	A loss of \$1431 from Restructuring, A gain of \$1321 from Legal Expense, A loss of \$144 from M & A Expense, A gain of \$38 from Derivatives, A loss of \$1224 from Impairments, A gain of \$125 from Asset Disposal, A gain of \$195 from Sale of Investment
A loss of \$68.000 from Merger/Acquisition Expense	A gain of \$10,623.000 from Discontinued Operations
A gain of \$ 5.000 from Investments, a gain from \$ 15.000 from disposal of asset, A loss of \$25.000 from impairment of asset	
2015 Q1	
GAAP Net Income includes, (in millions, after-tax):	2013 Q4
a loss of \$17.000 from Acquisition/Merger	GAAP Net Income Includes: (in millions, pre-tax)
a loss of \$167.000 from Various One-Time Items	A loss of \$708 from Restructuring, A loss of \$120 from Legal Expense, A loss of \$34 from M & A Expense, A gain of \$5 from Derivatives, A loss of \$176 from Impairments, A gain of \$125 from Assets Disposal, A gain of \$95 from Sale of Investment
a gain of \$5.000 from Discontinued Operations	a loss of \$58.000 from Discontinued Operations
2014 A1	
GAAP Net Income includes, (in millions):	2013 Q3
a pre-tax gain of \$288.000 from Disposal of Assets	GAAP Net Income includes, (in millions, after-tax):
a pre-tax loss of \$1,630.000 from Impairment/Legal	a loss of \$54.000 from Acquisition/Merger
a pre-tax loss of \$250.000 from Restructuring/Acquisition	a loss of \$1,223.000 from Various One-Time Items
an after-tax gain of \$48.000 from Discontinued Operations	a gain of \$11.000 from Discontinued Operations

Key Board Members

Name	Title	Organization
Ronald E Blaylock "Ron"	Founder	Blaylock & Partners Lp
	Partner/Founder	Gennx360 Capital Partners
	Board Member	Pfizer Inc
	Board Member	Wf Berkley Corp
	Board Member	Mebane Charitable Foundation I
Susan Desmond-Hellmann "Sue"	Board Member	Openai Inc
	Board Member	Pfizer Inc
	Board Member	National Resilience Inc
	Board Member	Pfizer Venture Investments
Suzanne Nora Johnson	Co-Chairman	Brookings Institution/The
	Chairman	Intuit Inc
	Board Member	Pfizer Inc
	Trustee	University Of Southern Califor
	Chairman	John & Mary R Markle Foundatio
	Trustee	Carnegie Institution Of Washin
	Trustee	University Of Southern Califor
	Board Member	Women'S World Banking Inc
	Board Member	Technoserve Inc
	Board Member	Council For Excellence In Govt
	Board Member	Children Now Inc
	Board Member	American Red Cross
	Board Member	Visa Intl Inc
Shantanu Narayen	Co-Founder	Pictra Inc
	Vice Chairman	Us-India Strategic Partnership
	Chairman/President/Ceo	Adobe Ventures Lp
	Chair/Ceo	Adobe Inc
	Lead Director	Pfizer Inc
	Chairman	Adobe Foundation
Susan Hockfield	Overseer	Boston Symphony Orchestra Inc

Ticker: PFE US EQUITY		Pfizer Inc									
Period Type		Annuals		Sector: Salud			Industry: Productos farmacéuticos		Sub-Industry: Productos farmacéuticos		
Annuals											
FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0fs	1FY	2FY	3FY
Key Financials											
	Actuals							LTM	Estimates		
For the Fiscal Period Ending	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	30/03/2025	30/03/2025	31/12/2025	31/12/2026	31/12/2027
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Netflix, Inc. opera como un servicio de streaming de suscripción y compañía de producción. Ofrece una gran variedad de programas de televisión, películas, ani											
Total Revenue	53,647.0	40,905.0	41,651.0	81,288.0	100,330.0	59,554.0	63,627.0	46,928.0	63,627.0	13,412.3	13,412.3
Growth Over Prior Year	2.1%	(23.8%)	1.8%	95.2%	23.4%	(40.6%)	6.8%	--	1.0%	1.0%	1.0%
Gross Profit	42,399.0	32,851.0	33,167.0	50,467.0	65,986.0	34,600.0	45,776.0	--	--	--	--
Margin %	79.0%	80.3%	79.6%	62.1%	65.8%	58.1%	71.9%	--	--	--	--
EBITDA	20,385.0	20,948.0	13,329.0	25,131.0	40,690.0	8,409.0	20,084.0	--	7,490.4	7,490.4	7,490.4
Margin %	38.0%	51.2%	32.0%	30.9%	40.6%	14.1%	31.6%	--	11.8%	55.8%	55.8%
EBIT	14,001.0	14,817.0	8,256.0	19,433.0	34,944.0	1,280.0	12,411.0	--	4,241.6	4,241.6	4,241.6
Margin %	26.1%	36.2%	19.8%	23.9%	34.8%	2.1%	19.5%	--	6.7%	31.6%	31.6%
Earnings from Cont. Ops.	11,179.0	10,738.0	6,666.0	22,459.0	31,401.0	2,173.0	8,051.0	--	--	--	--
Margin %	20.8%	26.3%	16.0%	27.6%	31.3%	3.6%	12.7%	--	--	--	--
Net Income	11,153.0	16,026.0	9,159.0	21,979.0	31,372.0	2,119.0	8,031.0	--	3,176.8	3,176.8	3,176.8
Margin %	20.8%	39.2%	22.0%	27.0%	31.3%	3.6%	12.6%	--	5.0%	23.7%	23.7%
Diluted EPS Excl. Extra Items	1.9	1.9	1.2	3.9	5.5	0.4	1.4	--	0.6	0.6	0.6
Growth Over Prior Year	(47.2%)	1.6%	(37.6%)	233.1%	39.2%	(93.2%)	281.1%	--	(5.5%)	(5.5%)	(5.5%)

Ticker:	PFE US EQUITY	PFE US EQUITY	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Income Statement											
Income Sheet as of:	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Revenue	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,651.00	81,288.00	91,793.00	51,972.00	55,239.00
Other Revenue	-	-	-	-	-	-	-	-	8,537.00	7,582.00	8,388.00
Total Revenue	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,651.00	81,288.00	100,330.00	59,554.00	63,627.00
Cost Of Goods Sold	9,577.00	9,648.00	12,329.00	11,228.00	11,248.00	8,054.00	8,484.00	30,821.00	34,344.00	24,954.00	17,851.00
Gross Profit	40,028.00	39,203.00	40,495.00	41,318.00	42,399.00	32,851.00	33,167.00	50,467.00	65,986.00	34,600.00	45,776.00
Selling General & Admin Exp.	14,347.00	15,961.00	16,561.00	15,155.00	15,499.00	5,220.00	12,170.00	16,974.00	16,005.00	22,641.00	22,543.00
R & D Exp.	8,393.00	7,690.00	7,872.00	7,683.00	8,006.00	8,385.00	9,393.00	10,360.00	11,428.00	10,679.00	10,822.00
Depreciation & Amort.	4,039.00	3,728.00	4,056.00	4,758.00	4,893.00	4,429.00	3,348.00	3,700.00	3,609.00	-	-
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
Operating Expense., Total	26,779.00	27,379.00	28,489.00	27,596.00	28,398.00	18,034.00	24,911.00	31,034.00	31,042.00	33,320.00	33,365.00
Operating Income	13,249.00	11,824.00	12,006.00	13,722.00	14,001.00	14,817.00	8,256.00	19,433.00	34,944.00	1,280.00	12,411.00
Interest Expense	1,360.00	1,199.00	1,186.00	1,270.00	1,316.00	1,573.00	1,449.00	1,291.00	1,238.00	2,209.00	3,091.00
Interest Income	425.00	471.00	470.00	391.00	333.00	225.00	73.00	36.00	251.00	1,624.00	545.00
Net Interest Exp.	935.00	728.00	716.00	879.00	983.00	1,348.00	1,376.00	1,255.00	987.00	585.00	2,546.00
Currency Exchange Gains (Loss)	-	806.00	-	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	74.00	1,325.00	2,939.00	538.00	1,133.00	2,148.00	(156.00)	(6,133.00)	(772.00)	(363.00)	1,842.00
EBT Excl. Unusual Items	12,240.00	8,965.00	8,351.00	12,305.00	11,885.00	11,321.00	7,036.00	24,311.00	34,729.00	1,058.00	8,023.00
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-	-	-	-	-	-	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	-	-	-	-	-	-	-	-	-	-	-
Other Unusual Items	-	-	-	-	-	-	-	-	-	-	-
EBT Incl. Unusual Items	12,240.00	8,965.00	8,351.00	12,305.00	11,885.00	11,321.00	7,036.00	24,311.00	34,729.00	1,058.00	8,023.00
Income Tax Expense	3,120.00	1,990.00	1,123.00	(9,048.00)	706.00	583.00	370.00	1,852.00	3,328.00	(1,115.00)	(28.00)
Earnings from Cont. Ops.	9,120.00	6,975.00	7,228.00	21,353.00	11,179.00	10,738.00	6,666.00	22,459.00	31,401.00	2,173.00	8,051.00
Extraord. Item & Account. Change	(48.00)	(11.00)	(18.00)	(2.00)	(10.00)	(5,318.00)	(2,529.00)	434.00	(6.00)	15.00	(11.00)
Minority Int. in Earnings	33.00	26.00	31.00	47.00	36.00	30.00	36.00	46.00	35.00	39.00	31.00
Net Income	9,135.00	6,960.00	7,215.00	21,308.00	11,153.00	16,026.00	9,159.00	21,979.00	31,372.00	2,119.00	8,031.00
Pref. Dividends	2.00	2.00	2.00	1.00	1.00	-	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
NI to Common Incl Extra Items	9,133.00	6,958.00	7,213.00	21,307.00	11,152.00	16,026.00	9,159.00	21,979.00	31,372.00	2,119.00	8,031.00
Abnormal Losses (Gains)	3,618.00	5,369.00	8,789.00	2,554.00	3,429.00	(2,791.00)	4,947.00	2,496.00	5,299.00	6,137.00	6,664.00
Tax Effect on Abnormal Items	(1,266.30)	(1,879.15)	(3,076.15)	(11,396.54)	(1,049.67)	(813.89)	(949.34)	(1,406.35)	(1,129.06)	(1,266.11)	(1,587.07)
NI to Common Excl. Extra Items	11,484.70	10,447.85	12,925.85	12,464.46	13,531.33	12,421.11	13,156.66	23,068.65	35,541.94	6,989.89	13,107.93
Per Share Items											
Basic EPS	1.44	1.13	1.18	3.57	1.90	2.88	1.65	3.92	5.59	0.38	1.42
Basic EPS Excl. Extra Items	1.43	1.13	1.18	3.57	1.90	1.92	1.19	4.00	5.59	0.38	1.42
Weighted Avg. Basic Shares Out.	6,346.00	6,176.00	6,089.00	5,970.00	5,872.00	5,569.00	5,555.00	5,601.00	5,608.00	5,643.00	5,664.00
Diluted EPS	1.42	1.11	1.17	3.52	1.87	2.82	1.63	3.85	5.47	0.37	1.41
Diluted EPS Excl. Extra Items	1.41	1.11	1.17	3.52	1.86	1.89	1.18	3.93	5.47	0.37	1.41
Weighted Avg. Diluted Shares Out.	6,424.00	6,257.00	6,159.00	6,058.00	5,977.00	5,675.00	5,632.00	5,708.00	5,733.00	5,709.00	5,700.00
Normalized Basic EPS	2.26	2.20	2.40	2.65	3.00	2.95	2.22	4.42	6.58	1.85	3.12
Normalized Diluted EPS	1.78	1.67	2.10	2.06	2.26	1.25	1.89	4.12	6.20	1.22	2.30
Dividends per Share											
Payout Ratio %	72.65	99.57	101.55	36.43	72.73	75.93	128.19	39.33	28.81	436.55	119.41
Supplemental Items											
EBITA	17,288.00	15,552.00	16,062.00	18,480.00	18,894.00	15,193.00	11,996.00	23,640.00	39,235.00	6,852.00	18,357.00
EBIT	13,249.00	11,824.00	12,006.00	13,722.00	14,001.00	14,817.00	8,256.00	19,433.00	34,944.00	1,280.00	12,411.00
As Reported Total Revenue*	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,651.00	81,288.00	100,330.00	59,554.00	63,627.00
Effective Tax Rate %	25.49	22.20	13.45	-	5.94	5.15	5.26	7.62	9.58	-	-
Normalized Net Income	11,436.70	10,436.85	12,907.85	12,462.46	13,521.33	7,103.11	10,627.66	23,502.65	35,535.94	7,004.89	13,096.93
Interest Capitalized	41.00	32.00	61.00	72.00	73.00	88.00	96.00	108.00	124.00	160.00	182.00
Supplemental Operating Expense Items											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	586.00	669.00	691.00	840.00	949.00	687.00	755.00	1,182.00	872.00	525.00	877.00
Stock-Based Comp., Total	586.00	669.00	691.00	840.00	949.00	687.00	755.00	1,182.00	872.00	525.00	877.00

Ticker:	PFE US EQUITY	PFE US EQUITY	Ascend ▾	Currency	Reporting Change	USD
Period Type	Annuals ▾	Consolidated	Yes ▾	Accounting	Mixed ▾	

Pfizer Inc

	Sector: Salud			Industry: Productos farmacéuticos			Sub-Industry: Productos farmacéuticos				
Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Balance Sheet											
Balance Sheet as of:	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
ASSETS											
Cash And Equivalents	3,343.00	3,641.00	2,595.00	1,342.00	1,139.00	1,121.00	1,786.00	1,944.00	416.00	2,853.00	1,043.00
Short Term Investments	32,779.00	19,649.00	15,255.00	18,650.00	17,694.00	8,525.00	10,437.00	29,125.00	22,316.00	9,837.00	19,434.00
Total Cash & ST Investments	36,122.00	23,290.00	17,850.00	19,992.00	18,833.00	9,646.00	12,223.00	31,069.00	22,732.00	12,690.00	20,477.00
Accounts & Notes Receivable	8,401.00	8,176.00	8,225.00	8,221.00	8,025.00	6,772.00	7,913.00	11,479.00	10,952.00	11,177.00	11,463.00
Total Receivables	8,401.00	8,176.00	8,225.00	8,221.00	8,025.00	6,772.00	7,913.00	11,479.00	10,952.00	11,177.00	11,463.00
Inventories	5,663.00	7,513.00	6,783.00	7,579.00	7,509.00	7,068.00	8,019.00	9,059.00	8,981.00	10,190.00	10,851.00
Prepaid Exp.	-	-	-	-	-	-	-	-	-	-	-
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	5,409.00	4,825.00	6,091.00	5,349.00	15,559.00	9,317.00	6,912.00	8,086.00	8,594.00	9,276.00	7,567.00
Total Current Assets	55,595.00	43,804.00	38,949.00	41,141.00	49,926.00	32,803.00	35,067.00	59,693.00	51,259.00	43,333.00	50,358.00
Net Property, Plant & Equipment	11,760.00	13,766.00	13,318.00	13,865.00	13,385.00	14,257.00	15,131.00	17,721.00	19,275.00	21,865.00	20,682.00
Long-term Investments	17,518.00	15,999.00	7,116.00	7,015.00	2,767.00	20,147.00	20,262.00	21,526.00	15,069.00	15,368.00	2,227.00
Deferred Charges, LT	1,944.00	1,794.00	1,812.00	1,855.00	1,924.00	1,911.00	2,383.00	3,341.00	6,693.00	3,706.00	8,662.00
Other Long-Term Assets	80,749.00	92,018.00	110,420.00	107,921.00	91,420.00	98,476.00	81,386.00	79,195.00	104,909.00	142,229.00	131,467.00
Total Assets	167,566.00	167,381.00	171,615.00	171,797.00	159,422.00	167,594.00	154,229.00	181,476.00	197,205.00	226,501.00	213,396.00
LIABILITIES											
Accrued Exp.	1,841.00	2,359.00	2,487.00	2,196.00	2,397.00	2,390.00	3,049.00	3,332.00	3,407.00	2,776.00	3,838.00
Short-term Borrowings	5,141.00	10,159.00	10,688.00	9,953.00	8,831.00	16,464.00	3,023.00	2,690.00	3,565.00	10,877.00	7,302.00
Accounts Payable	3,210.00	3,620.00	4,536.00	4,656.00	4,674.00	3,877.00	4,283.00	5,578.00	6,809.00	6,710.00	5,633.00
Curr. Income Taxes Payable	531.00	418.00	437.00	477.00	1,265.00	980.00	1,049.00	1,266.00	1,587.00	2,349.00	2,910.00
Other Current Liabilities	10,864.00	12,842.00	12,967.00	13,145.00	14,691.00	13,583.00	14,516.00	29,806.00	26,770.00	25,082.00	23,312.00
Total Current Liabilities	21,587.00	29,398.00	31,115.00	30,427.00	31,858.00	37,304.00	25,920.00	42,672.00	42,138.00	47,794.00	42,995.00
Long-Term Debt	31,541.00	28,740.00	31,398.00	33,538.00	32,909.00	36,985.00	38,241.00	38,705.00	35,481.00	64,164.00	59,691.00
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	42,817.00	44,245.00	49,262.00	36,176.00	30,897.00	29,859.00	26,595.00	22,637.00	23,669.00	25,255.00	22,213.00
Total Liabilities	95,945.00	102,383.00	111,775.00	100,141.00	95,664.00	104,148.00	90,756.00	104,014.00	101,288.00	137,213.00	124,899.00
Pref. Stock, Non-Redeem.	29.00	26.00	24.00	21.00	19.00	17.00	-	-	-	-	-
Total Pref. Equity	29.00	26.00	24.00	21.00	19.00	17.00	-	-	-	-	-
Minority Interest	321.00	278.00	296.00	348.00	351.00	303.00	235.00	262.00	256.00	274.00	294.00
Additional Paid In Capital	79,432.00	81,475.00	83,146.00	84,742.00	86,720.00	87,896.00	89,144.00	91,064.00	92,278.00	93,109.00	94,083.00
Retained Earnings	72,176.00	71,993.00	71,774.00	85,291.00	89,554.00	97,670.00	90,392.00	103,394.00	125,656.00	118,353.00	116,725.00
Treasury Stock	(73,021.00)	(79,252.00)	(84,364.00)	(89,425.00)	(101,610.00)	(110,801.00)	(110,988.00)	(111,361.00)	(113,969.00)	(114,487.00)	(114,763.00)
Comprehensive Inc. and Other	(7,316.00)	(9,522.00)	(11,036.00)	(9,321.00)	(11,276.00)	(11,639.00)	(5,310.00)	(5,897.00)	(8,304.00)	(7,961.00)	(7,842.00)
Total Common Equity	71,592.00	64,972.00	59,816.00	71,635.00	63,739.00	63,429.00	63,473.00	77,462.00	95,917.00	89,288.00	88,497.00
Total Equity	71,621.00	64,998.00	59,840.00	71,656.00	63,758.00	63,446.00	63,473.00	77,462.00	95,917.00	89,288.00	88,497.00
Total Liabilities And Equity	167,566.00	167,381.00	171,615.00	171,797.00	159,422.00	167,594.00	154,229.00	181,476.00	197,205.00	226,501.00	213,396.00
Supplemental Items											
Total Shares Out. on Filing Date	6,291.00	6,175.00	6,070.00	5,979.00	5,717.00	5,534.00	5,567.00	5,620.00	5,616.00	5,646.00	5,667.00
Total Shares Out. on Balance Sheet Date	6,291.00	6,175.00	6,070.00	5,979.00	5,717.00	5,534.00	5,567.00	5,620.00	5,616.00	5,646.00	5,667.00
Book Value/Share	11.33	10.48	9.81	11.92	11.09	11.41	11.36	13.74	17.03	15.77	15.56
Tangible Book Value	(5,965.00)	(23,904.00)	(47,577.00)	(33,405.00)	(25,234.00)	(19,012.00)	(14,655.00)	2,846.00	915.00	(43,667.00)	(35,735.00)
Tangible Book Value/Share	(0.95)	(3.87)	(7.84)	(5.59)	(4.41)	(3.44)	(2.63)	0.51	0.16	(7.73)	(6.31)
Total Debt	36,682.00	38,899.00	42,086.00	43,491.00	41,740.00	53,449.00	41,264.00	41,395.00	39,046.00	75,041.00	66,993.00
Net Debt	560.00	15,609.00	24,236.00	29,499.00	22,907.00	43,803.00	29,041.00	10,326.00	16,314.00	62,351.00	46,516.00
Total Minority Interest	321.00	278.00	296.00	348.00	351.00	303.00	235.00	262.00	256.00	274.00	294.00
Inventory Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	510.00	867.00	793.00	788.00	546.00	672.00	716.00	994.00	859.00	1,007.00	976.00
Work in Progress Inventory	3,248.00	3,932.00	3,696.00	3,908.00	4,701.00	4,131.00	4,436.00	4,424.00	5,519.00	5,688.00	6,101.00
Finished Goods Inventory	1,905.00	2,714.00	2,294.00	2,883.00	2,262.00	2,265.00	2,867.00	3,641.00	2,603.00	3,495.00	3,774.00
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	412.00	384.00	609.00	584.00	541.00	493.00	508.00	492.00	449.00	470.00	438.00
Full Time Employees	78,300.00	97,900.00	96,500.00	90,200.00	92,400.00	88,000.00	78,500.00	79,000.00	83,000.00	88,000.00	81,000.00

Ticker:	PFE US EQUITY	Sort	Ascend	Currency Selection	☒ Reporting	☐ Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting Standard	Mixed		

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Cash Flow											
For the Fiscal Period Ending	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Net Income	9,135.00	6,960.00	7,215.00	21,308.00	11,153.00	16,026.00	9,159.00	21,979.00	31,372.00	2,119.00	8,031.00
Depreciation & Amort., Total	5,537.00	5,157.00	5,757.00	6,269.00	6,384.00	5,755.00	4,681.00	5,191.00	5,064.00	6,290.00	7,013.00
Other Non-Cash Adj	1,300.00	2,730.00	2,561.00	(12,169.00)	(702.00)	(3,583.00)	3,501.00	10,270.00	(8,668.00)	(3,804.00)	1,031.00
Changes in Non-Cash Capital	1,112.00	(159.00)	368.00	1,394.00	(1,008.00)	(5,610.00)	(2,938.00)	(4,860.00)	1,499.00	4,095.00	(3,331.00)
Cash from Ops.	17,084.00	14,688.00	15,901.00	16,802.00	15,827.00	12,588.00	14,403.00	32,580.00	29,267.00	8,700.00	12,744.00
Capital Expenditure	(1,199.00)	(1,397.00)	(1,823.00)	(1,956.00)	(2,042.00)	(2,046.00)	(2,226.00)	(2,711.00)	(3,236.00)	(3,907.00)	(2,909.00)
Sale of Property, Plant, and Equipment	-	-	-	-	-	-	-	-	-	-	-
Cash Acquisitions	(10,718.00)	(9,542.00)	(8,011.00)	(3,537.00)	(1,797.00)	(201.00)	(597.00)	(1,068.00)	(1,913.00)	(204.00)	(180.00)
Proceeds from Investment	6,145.00	6,929.00	11,254.00	3,579.00	6,244.00	232.00	723.00	649.00	641.00	1,979.00	1,570.00
Divestitures	-	-	-	-	-	-	-	-	-	-	-
Invest. in Marketable & Equity Securt.	-	-	-	-	-	-	-	-	-	-	-
Other Investing Activities	118.00	1,030.00	(9,231.00)	(2,826.00)	2,120.00	(1,930.00)	(2,171.00)	(19,416.00)	(11,275.00)	(30,146.00)	4,171.00
Cash from Investing	(5,654.00)	(2,980.00)	(7,811.00)	(4,740.00)	4,525.00	(3,945.00)	(4,271.00)	(22,546.00)	(15,783.00)	(32,278.00)	2,652.00
Net Short Term Debt Issued/Repaid	(1,838.00)	4,309.00	(714.00)	(61.00)	(2,343.00)	10,628.00	(13,974.00)	(96.00)	(218.00)	7,683.00	(4,909.00)
Long-Term Debt Issued	4,491.00	-	10,976.00	5,274.00	4,974.00	4,942.00	5,222.00	997.00	-	30,831.00	-
Long-Term Debt Repaid	(2,110.00)	(2,990.00)	(7,689.00)	(6,154.00)	(3,566.00)	(6,806.00)	(4,003.00)	(2,004.00)	(3,298.00)	(2,569.00)	(2,250.00)
Total Debt Issued/Repaid	543.00	1,319.00	2,573.00	(941.00)	(935.00)	8,764.00	(12,755.00)	(1,103.00)	(3,516.00)	35,945.00	(7,159.00)
Pref. Dividends Paid	(6,609.00)	(6,940.00)	(7,317.00)	(7,659.00)	(7,978.00)	(8,043.00)	(8,440.00)	(8,729.00)	(8,983.00)	(9,247.00)	(9,512.00)
Total Dividends Paid	(6,609.00)	(6,940.00)	(7,317.00)	(7,659.00)	(7,978.00)	(8,043.00)	(8,440.00)	(8,729.00)	(8,983.00)	(9,247.00)	(9,512.00)
Increase in Capital Stocks	1,002.00	1,263.00	1,019.00	862.00	1,259.00	-	-	-	-	-	-
Decrease in Capital Stocks	(5,000.00)	(6,160.00)	(5,000.00)	(5,000.00)	(12,198.00)	(8,865.00)	-	-	(2,000.00)	-	-
Special Dividend Paid	-	-	-	-	-	-	-	-	-	-	-
Incr(Decr) in Deposits	-	-	-	-	-	-	-	-	-	-	-
Incr(Decr) Insurance Reserves	-	-	-	-	-	-	-	-	-	-	-
Other Financing Activities	(206.00)	(891.00)	(411.00)	(559.00)	(705.00)	(374.00)	11,538.00	(43.00)	(500.00)	(672.00)	(535.00)
Cash from Financing	(10,270.00)	(11,409.00)	(9,136.00)	(13,297.00)	(20,557.00)	(8,518.00)	(9,657.00)	(9,875.00)	(14,999.00)	26,026.00	(17,206.00)
Net Change in Cash	1,160.00	299.00	(1,046.00)	(1,235.00)	(205.00)	125.00	475.00	159.00	(1,515.00)	2,448.00	(1,810.00)
Supplemental Items											
Cash Interest Paid	1,550.00	1,302.00	1,451.00	1,518.00	1,311.00	1,587.00	1,641.00	1,467.00	1,442.00	2,215.00	3,227.00
Cash Taxes Paid	2,100.00	2,383.00	2,521.00	2,489.00	3,655.00	3,664.00	3,153.00	7,427.00	7,867.00	3,147.00	3,605.00
Free Cash Flow	15,885.00	13,291.00	14,078.00	14,846.00	13,785.00	10,542.00	12,177.00	29,869.00	26,031.00	4,793.00	9,835.00
Change in Net Working Capital	-	-	-	-	-	-	-	-	-	-	-

Ticker: PFE US EQUITY

Period Type: Annuals

Sort: Ascend

Consolidated: Yes

Accounting: Mixed

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y		-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Multiples		31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
TEV / LTM Total Revenue	Close	4.0x	4.4x	4.2x	4.6x	5.1x	6.4x	5.6x	4.2x	3.0x	3.8x	3.1x
	Average	3.8x	4.2x	4.4x	4.3x	4.8x	4.6x	6.0x	6.3x	3.6x	2.2x	3.7x
	High	4.1x	4.5x	5.0x	4.7x	5.5x	6.4x	6.9x	9.0x	4.0x	3.8x	4.0x
	Low	3.5x	3.9x	3.9x	4.0x	4.3x	4.0x	4.9x	4.2x	3.0x	1.6x	3.1x
TEV / LTM EBITDA	Close	10.5x	12.7x	12.5x	12.0x	13.4x	12.5x	17.6x	13.6x	7.5x	26.8x	9.8x
	Average	9.2x	11.1x	12.7x	12.8x	12.7x	12.1x	11.8x	19.8x	11.5x	5.6x	26.2x
	High	10.5x	12.7x	14.3x	13.9x	14.6x	13.5x	17.5x	28.0x	13.1x	26.8x	28.6x
	Low	8.3x	10.2x	11.3x	12.0x	11.2x	10.4x	9.7x	13.6x	7.5x	4.0x	9.8x
TEV / LTM EBIT	Close	14.9x	18.2x	18.5x	17.5x	19.5x	17.6x	28.2x	17.6x	8.7x	160.7x	15.7x
	Average	13.0x	15.8x	18.3x	19.0x	18.5x	17.6x	16.7x	31.9x	14.9x	7.0x	156.9x
	High	14.9x	18.2x	20.5x	20.5x	21.2x	19.6x	28.2x	45.0x	16.9x	160.7x	171.7x
	Low	11.9x	14.4x	16.3x	17.5x	16.3x	15.2x	13.6x	17.5x	8.7x	4.7x	15.7x
Price / LTM EPS	Close	17.5x	19.4x	15.5x	17.6x	19.3x	31.2x	19.5x	14.3x	8.3x	23.5x	11.5x
	Average	16.3x	18.0x	18.6x	15.4x	18.0x	16.8x	27.8x	22.2x	12.1x	6.0x	22.8x
	High	17.6x	19.3x	21.2x	16.8x	21.3x	29.6x	33.9x	32.4x	13.8x	23.5x	25.7x
	Low	14.9x	16.4x	14.7x	14.1x	15.5x	14.4x	19.5x	14.3x	8.3x	4.2x	11.5x
Price / Book Value	Close	2.7x	3.1x	3.3x	3.0x	3.9x	3.4x	3.2x	4.3x	3.0x	1.8x	1.7x
	Average	2.4x	2.8x	3.0x	3.3x	3.1x	3.4x	3.1x	3.7x	3.6x	2.2x	1.8x
	High	2.6x	3.0x	3.4x	3.6x	3.7x	3.8x	3.7x	5.4x	4.1x	3.0x	2.0x
	Low	2.2x	2.6x	2.6x	2.9x	2.7x	2.9x	2.4x	2.9x	3.0x	1.5x	1.6x
Price / Tangible Book Value	Close	--	--	--	--	--	--	--	116.6x	314.5x	--	--
	Average	--	--	--	--	--	--	--	116.6x	99.2x	226.6x	--
	High	--	--	--	--	--	--	--	116.6x	314.5x	314.6x	--
	Low	--	--	--	--	--	--	--	116.6x	82.4x	160.4x	--
Price / Cash Flow	Close	11.6x	13.6x	12.4x	12.9x	16.2x	17.3x	14.2x	10.2x	9.8x	18.7x	11.8x
	Average	11.1x	11.9x	13.1x	12.4x	13.2x	14.1x	15.4x	16.2x	8.6x	7.1x	18.1x
	High	12.0x	12.9x	14.9x	13.5x	15.6x	16.4x	18.8x	23.6x	9.8x	18.7x	20.4x
	Low	10.1x	10.9x	11.4x	11.3x	11.3x	12.0x	11.9x	10.2x	7.2x	5.0x	11.8x
TEV / LTM FCF	Close	12.4x	15.0x	14.0x	14.6x	18.6x	20.7x	16.8x	11.1x	11.0x	33.9x	15.3x
	Average	11.9x	12.8x	14.5x	14.0x	14.9x	16.1x	18.4x	19.2x	9.3x	8.1x	32.8x
	High	12.8x	14.2x	16.4x	15.3x	17.6x	19.6x	22.5x	27.9x	11.0x	33.9x	37.0x
	Low	10.9x	11.7x	12.6x	12.8x	12.8x	13.8x	14.3x	11.1x	7.8x	5.6x	15.3x
Dividend Yield	Close	3.3	3.5	3.7	3.6	3.2	3.7	4.2	2.7	3.1	5.7	6.4
	Average	3.3	3.3	3.6	3.7	3.5	3.7	4.2	3.7	3.2	4.4	5.9
	High	3.7	3.7	4.1	4.1	4.1	4.3	5.4	4.6	3.8	6.1	6.7
	Low	3.1	3.0	3.2	3.4	3.0	3.3	3.4	2.5	2.8	3.1	5.3

Ticker: PFE US EQUITY		PFE US EQUITY		Ascend	Accounting	Mixed
Period Type	Quarters	Consolidated	Yes			

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10Q	-9Q	-8Q	-7Q	-6Q	-5Q	-4Q	-3Q	-2Q	-1Q	0Q
Ratios											
For the Fiscal Period Ending											
	02/10/2022	31/12/2022	02/04/2023	02/07/2023	01/10/2023	31/12/2023	31/03/2024	30/06/2024	29/09/2024	31/12/2024	30/03/2025
Profitability											
Return on Assets	15.9%	16.6%	15.3%	10.3%	5.1%	1.0%	-0.1%	-1.2%	2.0%	3.7%	3.7%
Return on Capital	25.2%	25.6%	23.6%	15.7%	8.2%	2.6%	1.2%	-0.1%	4.2%	6.6%	6.5%
Return on Equity	35.4%	36.3%	31.7%	23.1%	11.1%	2.3%	-0.3%	-2.8%	4.5%	9.1%	8.6%
Margin Analysis											
Gross Margin	73.2%	60.3%	73.6%	75.1%	30.0%	48.1%	77.3%	75.2%	70.3%	66.7%	79.3%
SG&A Margin	14.3%	18.2%	18.1%	26.3%	24.2%	30.7%	23.2%	27.6%	18.2%	24.1%	21.9%
EBITDA Margin	38.4%	39.9%	40.2%	35.5%	22.9%	12.3%	9.2%	7.3%	21.0%	30.5%	30.3%
EBT Margin	33.6%	34.8%	34.4%	28.1%	14.0%	1.7%	-2.6%	-4.7%	9.6%	18.5%	19.3%
Earnings from Cont. Ops Margin	39.5%	18.1%	35.4%	16.9%	-25.9%	-29.4%	27.6%	7.6%	28.0%	13.2%	27.3%
Net Income Margin	38.0%	20.6%	30.0%	17.9%	-18.0%	-23.1%	20.9%	0.3%	25.2%	2.3%	21.6%
Normalized Net Income Margin	42.1%	23.7%	33.3%	21.8%	-12.7%	-1.3%	24.0%	16.7%	28.6%	12.8%	31.8%
Free Cash Flow Margin	40.2%	14.9%	0.4%	-16.3%	20.0%	28.8%	2.6%	-18.2%	34.3%	32.7%	12.9%
Asset Turnover											
Total Asset Turnover	0.7x	0.7x	0.7x	0.8x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x
Fixed Asset Turnover	6.7x	5.4x	5.8x	4.8x	4.1x	7x	3.1x	3.1x	3.7x	5.0x	5.4x
Accounts Receivable Turnover	7.1x	8.4x	7.5x	6.7x	5.1x	5.6x	4.8x	5.7x	4.7x	5.6x	5.5x
Inventory Turnover	5.8x	5.0x	5.7x	7.7x	7.6x	7.6x	7.5x	7.7x	5.9x	5.7x	5.6x
Quick Term Liquidity											
Current Ratio	1.6x	1.7x	1.4x	2.1x	7.4x	0.9x	1.0x	0.9x	1.0x	1.7x	1.9x
Quick Ratio	1.7x	1.8x	1.6x	2.1x	7.4x	0.8x	0.8x	0.8x	0.8x	1.7x	1.8x
Cash from Ops. To Fin. Liab.	0.8x	0.5x	0.7x	1.3x	1.4x	0.5x	0.5x	0.7x	0.7x	0.5x	0.5x
Acc. Change Sales Chg.	51.0x	40.9x	48.9x	71.4x	71.4x	71.4x	70.1x	70.1x	76.9x	65.1x	66.5x
Acc. Change Investments Chg.	66.0x	95.9x	171.6x	168.6x	137.7x	140.7x	168.4x	168.4x	304.6x	315.7x	378.1x
Acc. Change Payables Chg.	56.1x	46.0x	74.7x	76.7x	76.7x	86.7x	86.7x	87.7x	97.7x	177.0x	114.1x
Acc. Change Provisions Payable	40.4x	30.7x	67.8x	171.1x	138.7x	114.0x	148.8x	154.7x	188.5x	154.8x	181.0x
Lower Term Solvency											
Total Debt/Equity	58.5%	40.7%	55.5%	65.8%	65.4%	84.0%	75.1%	78.9%	79.1%	75.7%	48.5%
Total Debt/Total Capital	26.7%	26.7%	26.7%	47.0%	47.0%	77.1%	66.4%	65.6%	67.9%	67.7%	43.8%
LT Debt/Equity	55.1%	26.1%	29.1%	58.0%	58.0%	86.0%	56.7%	56.7%	57.7%	57.7%	43.7%
Total Liabilities/Total Assets	74.8%	50.0%	74.6%	89.7%	80.5%	99.0%	99.0%	99.0%	98.1%	98.4%	98.9%
EBIT / Interest Exp.	29.56x	14.01x	30.58x	4.57x	-4.95x	-6.77x	5.19x	1.70x	6.53x	3.18x	5.77x
EBITDA / Interest Exp.	52.56x	15.86x	35.76x	13.69x	-3.80x	-5.27x	7.40x	2.60x	8.56x	4.60x	7.60x
EBITDA / APPE / Interest Exp.	79.86x	15.66x	31.64x	5.67x	-3.85x	-5.51x	6.50x	2.70x	7.73x	4.36x	7.53x
Total Debt/EBITDA	0.60x	0.60x	0.60x	4.07x	4.07x	10.77x	14.47x	14.47x	14.47x	14.47x	4.07x
Net Debt/EBITDA	0.01x	0.01x	0.01x	0.70x	1.77x	8.55x	11.76x	15.77x	4.56x	7.90x	7.56x
Adjusted Y. Growth	4.6%	6.6%	6.7%	4.7%	9.6%	3.4%	9.4%	3.9%	5.6%	9.6%	4.7%
Growth Rate Prior Year											
Total Revenue	(5.86)	1.9%	(78.06)	(51.16)	(41.56)	(40.06)	(18.56)	7.1%	9.8%	31.9%	(7.86)
Gross Profit	(17.56)	1.8%	(48.86)	(28.16)	(25.16)	(25.16)	(15.46)	7.7%	21.8%	69.1%	(5.56)
EBITDA	35.7%	38.1%	(74.16)	(71.96)	(118.56)	(144.36)	(77.16)	(77.46)	(45.86)	(75.86)	(8.76)
EBT	57.7%	39.7%	(75.16)	(74.16)	(173.56)	(198.56)	(154.56)	(77.76)	(178.56)	(177.76)	(18.56)
EBT	45.1%	46.0%	(80.46)	(87.06)	(158.46)	(197.86)	(177.16)	(54.16)	(74.46)	(154.86)	(8.96)
Earnings from Cont. Ops	5.7%	5.8%	(4.86)	(4.86)	(14.16)	(14.16)	(14.16)	(14.16)	(14.16)	(14.16)	(14.16)
Net Income	5.7%	47.7%	(79.16)	(79.16)	(177.76)	(167.46)	(167.46)	(167.46)	(167.46)	(117.76)	(4.86)
Normalized Net Income	6.5%	15.1%	(77.16)	(77.16)	(177.76)	(167.46)	(167.46)	(167.46)	(167.46)	(117.76)	(14.16)
Adjusted EPS before Taxes	5.6%	40.7%	(79.76)	(79.76)	(177.76)	(167.46)	(167.46)	(167.46)	(168.16)	(111.96)	(5.56)
Accounts Receivable	35.1%	(4.66)	(7.06)	(71.56)	(81.06)	7.1%	(10.76)	11.4%	30.4%	7.6%	7.8%
Inventory	10.1%	(8.06)	(4.46)	(1.46)	7.9%	15.4%	1.4%	1.4%	1.4%	6.4%	(8.06)
Net PP&E	7.0%	8.7%	17.9%	14.7%	15.7%	14.8%	10.5%	9.8%	(5.46)	(5.46)	(5.46)
Total Assets	6.0%	8.7%	6.4%	17.7%	10.1%	14.9%	13.0%	(1.86)	7.1%	(5.46)	(5.46)
Table Book Value	(14.56)	(67.86)	709.56	(77.56)	(65.76)	(4.847.06)	(4.847.06)	(797.56)	(797.56)	(158.56)	(154.76)
Common Equity	17.4%	17.4%	17.4%	17.4%	17.4%	17.4%	17.4%	17.4%	17.4%	17.4%	17.4%
Cash from Ops.	(8.16)	(71.96)	(81.56)	(114.96)	(65.76)	15.4%	(10.16)	47.4%	84.5%	28.3%	15.4%
Capital Expenditures	30.1%	27.1%	21.7%	12.7%	12.7%	4.2%	(2.76)	(2.76)	(19.46)	(19.46)	(19.46)
Unlevered Free Cash Flow	(10.96)	(76.46)	(88.86)	(178.66)	(70.96)	15.4%	479.8%	15.4%	179.1%	38.3%	308.8%
Unlevered Free Cash Flow	(11.6)	(48.66)	(148.66)	(298.66)	(298.66)	99.7%	1.08x	1.08x	1.08x	1.08x	1.08x
Dividend per Share	7.6%	7.6%	7.6%	7.6%	7.6%	7.6%	7.6%	7.6%	7.6%	7.6%	7.6%
F&B Prior Year											
Total Revenue	48.4%	44.1%	17.8%	(17.06)	(75.86)	(71.86)	(71.86)	(181.86)	(11.46)	(14.56)	(11.96)
Gross Profit	41.4%	34.4%	14.4%	(44.46)	(44.46)	(14.46)	(14.46)	(14.46)	(14.46)	(14.46)	(14.46)
EBITDA	67.9%	86.7%	16.7%	(76.76)	--	--	(75.86)	(54.86)	(18.46)	(16.76)	(18.76)
EBT	68.1%	86.9%	17.4%	(77.06)	--	--	(77.06)	(60.06)	(18.46)	(18.46)	(18.46)
EBT	61.1%	154.1%	18.1%	(17.46)	--	--	(14.06)	(71.96)	(75.06)	(76.46)	(74.46)
Earnings from Cont. Ops	70.7%	180.9%	6.4%	(16.66)	--	--	(16.66)	(16.66)	(16.66)	(16.66)	(16.66)
Net Income	147.1%	147.8%	6.4%	(16.16)	--	--	(17.16)	(89.46)	(78.06)	(71.46)	(74.06)
Normalized Net Income	146.1%	146.1%	6.4%	(16.16)	--	--	(16.16)	(89.46)	(77.06)	(71.46)	(74.06)
Adjusted EPS before Taxes	307.7%	181.7%	6.7%	(16.66)	--	--	(16.66)	(89.46)	(77.96)	(71.46)	(74.06)
Accounts Receivable	26.7%	17.6%	11.7%	(1.76)	(1.76)	(1.76)	(8.86)	(11.86)	(5.76)	7.1%	(1.96)
Inventory	1.7%	5.8%	6.0%	6.7%	8.7%	1.1%	4.4%	4.0%	1.0%	6.0%	6.0%
Net PP&E	3.4%	11.4%	10.1%	15.8%	6.5%	11.7%	9.7%	5.7%	6.0%	4.0%	5.1%
Total Assets	4.5%	11.1%	11.0%	15.8%	6.5%	11.7%	9.7%	5.7%	6.0%	4.0%	5.1%
Table Book Value	--	--	--	--	--	--	--	--	--	--	--
Common Equity	19.1%	21.0%	21.1%	18.4%	15.7%	7.4%	5.8%	(5.76)	(0.76)	(4.06)	(5.46)
Cash from Ops.	118.0%	(9.46)	(48.36)	(45.36)	(45.36)	(5.96)	(5.96)	--	(17.96)	29.6%	38.9%
Capital Expenditures	17.4%	17.9%	43.4%	50.5%	14.5%	2.9%	4.4%	(7.96)	(17.06)	(4.76)	(74.06)
Unlevered Free Cash Flow	145.9%	(11.56)	(86.56)	--	(49.16)	(7.76)	(74.46)	--	(18.96)	26.4%	397.5%
Unlevered Free Cash Flow	--	(79.96)	--	(79.96)	(17.96)	7.9%	7.9%	7.9%	7.9%	7.9%	7.9%
Dividend per Share	7.6%	7.6%	7.6%	7.6%	7.6%	7.6%	7.6%	7.6%	7.6%	7.6%	7.6%
F&B Prior Year											
Total Revenue	21.3%	32.1%	77.4%	6.7%	8.8%	7.8%	0.8%	(11.16)	(8.76)	(8.76)	(18.86)
Gross Profit	18.0%	30.1%	18.4%	4.7%	(21.76)	(7.76)	1.4%	(6.76)	(4.16)	(5.46)	(11.56)
EBITDA	(7.96)	49.7%	34.4%	4.4%	(198.46)	(151.46)	(9.46)	(16.46)	(16.46)	(16.46)	(16.46)
EBT	(7.96)	53.0%	29.4%	4.7%	(198.76)	(278.76)	(9.46)	(16.46)	(16.46)	(16.46)	(16.46)
EBT	(6.96)	107.1%	29.7%	1.9%	(211.96)	(287.96)	(4.46)	(41.96)	(4.96)	(7.76)	(7.76)
Earnings from Cont. Ops	4.7%	(148.46)	39.4%	--	(17.46)	(17.46)	(17.46)	(17.46)	(17.46)	(17.46)	(17.46)
Net Income	1.9%	(148.46)	18.7%	(11.46)	(17.76)	(74.46)	(18.46)	(18.46)	(18.46)	(18.46)	(17.76)
Normalized Net Income	47.7%	147.1%	18.7%	(17.76)	(17.76)	(17.76)	(17.76)	(17.76)	(17.76)	(17.76)	(17.76)
Adjusted EPS before Taxes	1.5%	(146.16)	10.1%	(18.86)	(27.06)	(77.06)	(18.86)	(17.96)	(17.96)	(17.96)	(17.96)
Accounts Receivable	18.4%	17.4%	7.4%	3.8%	1.7%	17.7%	7.7%	7.7%	6.7%	(0.76)	(0.66)
Inventory	5.0%	7.4%	4.7%	4.4%	5.7%	8.4%	8.4%	10.7%	4.7%	7.8%	7.8%
Net PP&E	1.0%	10.6%	6.7%	7.4%	11.1%	10.1%	8.7%	8.7%	5.1%	6.7%	6.7%
Total Assets	4.7%	5.6%	5.6%	7.4%	6.5%	11.7%	11.7%	8.4%	7.0%	5.6%	4.7%
Table Book Value	(174.96)	(154.96)	(144.16)	(154.96)	(154.46)	45.7%	47.6%	79.1%	401.46)	(151.86)	(74.96)
Common Equity	15.4%	15.4%	15.4%	15.4%	15.4%	15.4%	15.4%	15.4%	15.4%	15.4%	15.4%
Cash from Ops.	15.2%	(8.26)	(9.46)	(179.36)	(8.16)	2.0%	(8.56)	(152.66)	8.3%	12.3%	(5.76)
Capital Expenditures	13.3%	7.4%	24.2%	16.6%	8.2%	8.8%	8.9%	5.9%	2.9%	10.1%	4.7%
Unlevered Free Cash Flow	15.4%	(141.96)	(141.96)	(154.96)	(154.96)	51.8%	42.3%	(152.96)	12.4%	12.4%	(152.96)
Unlevered Free Cash Flow	21.9%	(21.06)	38.7%	(221.96)	(14.36)	(2.16)	19.7%	(305.86)	13.7%	23.1%	(202.86)
Dividend per Share	4.6%	4.6%	3.8%	3.8%	3.8%	3.8%	3.1%	3.1%	3.1%	3.1%	2.5%

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Capital Structure										
For the Fiscal Period Ending Currency	31/03/2024 USD		30/06/2024 USD		29/09/2024 USD		31/12/2024 USD		30/03/2025 USD	
	Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total
Hot Market Cdn										
ST Revenue	8,232.0	3.6%	11,944.0	5.2%	9,699.0	4.2%	7,302.0	3.4%	4,470.0	2.2%
LT Borrowings	61,307.0	27.0%	57,506.0	25.2%	58,002.0	24.9%	59,691.0	27.5%	57,639.0	28.1%
Pref Equity	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%
Total Capital	226,798.3	100.0%	228,012.7	100.0%	232,524.9	100.0%	217,338.5	100.0%	205,427.9	100.0%

[illegible]

Credit Ratios				
Net Debt/EBITDA	11.3x	15.3x	4.6x	2.4x
Total Debt/EBITDA	13.6x	17.0x	5.3x	3.4x
Operating Income/Total Debt	0.1x	0.0x	0.1x	0.0x
LTW FCF/Total Debt	0.1x	0.1x	0.1x	0.1x
LTW CFF/Total Debt	0.1x	0.1x	0.2x	0.2x
FFIT/Interest Expense	5.2x	1.3x	6.3x	3.2x
FFIT/Total Interest Expense	5.2x	1.3x	6.3x	3.2x
Degree of Financial Leverage	1.2x	4.5x	1.2x	1.5x
EBITDA/CAPEX/Interest Expense	6.5x	2.7x	7.7x	4.4x
EBITDA/Total Interest Expense	7.4x	3.5x	8.6x	5.6x

Debt Schedule									
Debt Schedule In Yr 1	---	---	---	---	---	---	---	---	---
Debt Schedule In Yr 2	---	---	---	---	---	---	---	---	---
Debt Schedule In Yr 3	---	---	---	---	---	---	---	---	---
Debt Schedule In Yr 4	---	---	---	---	---	---	---	---	---
Debt Schedule In Yr 5	---	---	---	---	---	---	---	---	---
Debt Schedule - Years 2 - 3	---	---	---	---	---	---	---	---	---
Debt Schedule - Years 4 - 5	---	---	---	---	---	---	---	---	---
Debt Schedule - Years 2 - 5	---	---	---	---	---	---	---	---	---
Debt Schedule Beyond Yr 5	---	---	---	---	---	---	---	---	---
Debt Schedule - Total Debt	69,539.0	100.0%	69,450.0	100.0%	67,701.0	100.0%	64,351.0	100.0%	62,109.0

[illegible]

Operations Leases (Rental Expense) Schedule									
Rental Expense - Year 1	--	--	--	--	--	443.0	13.9%	--	--
Rental Expense - Year 2	--	--	--	--	--	406.0	12.7%	--	--
Rental Expense - Year 3	--	--	--	--	--	361.0	11.3%	--	--
Rental Expense - Year 4	--	--	--	--	--	281.0	8.8%	--	--
Rental Expense - Year 5	--	--	--	--	--	239.0	7.5%	--	--
Rental Expense - Years 2 - 3	--	--	--	--	--	767.0	24.0%	--	--
Rental Expense - Years 4 - 5	--	--	--	--	--	520.0	16.3%	--	--
Rental Expense - Years 2 - 5	--	--	--	--	--	1,287.0	40.2%	--	--
Rental Expense Beyond Year 5	--	--	--	--	--	1,468.0	45.9%	--	--
Total Sublease Income	--	--	--	--	--	--	--	--	--
Future Min Oper Lease Obligations	--	--	--	--	--	3,198.0	100.0%	--	--

[illegible]

Purchase Obligations	--	--	--	4,100.0	--
----------------------	----	----	----	---------	----

Interest Rate Data				
W/Avg. Interest Rate - Long-term Debt	2017	2018	2019	2020
	3.50%	3.50%	3.50%	3.50%

Pfizer Inc

[illegible]**OPERATING PROFIT BEF TAX**

Ticker:	PFE US EQUITY	Sort	Ascend ▾	Currency	Reporting	Change	USD
Period Type	Annuals ▾	Consolidated	Yes ▾	Accounting	Mixed ▾		

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Pension											
For the Fiscal Period Ending	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Pension Net Periodic Cost											
Service Cost	472.00	495.00	440.00	464.00	136.00	125.00	146.00	130.00	116.00	85.00	87.00
Interest Cost	1,148.00	1,037.00	932.00	892.00	865.00	891.00	697.00	601.00	691.00	876.00	865.00
Expected Return on Plan Assets	(1,502.00)	(1,507.00)	(1,339.00)	(1,350.00)	(1,400.00)	(1,207.00)	(1,329.00)	(1,379.00)	(1,158.00)	(1,082.00)	(1,154.00)
Pension Expense (Income)	402.00	1,203.00	696.00	695.00	(2.00)	331.00	809.00	(2,011.00)	(129.00)	(423.00)	237.00
Other Postretirement Cost											
Service Cost	55.00	55.00	41.00	42.00	39.00	37.00	38.00	36.00	29.00	12.00	14.00
Interest Cost	169.00	117.00	101.00	90.00	72.00	75.00	49.00	29.00	27.00	21.00	23.00
Expected Return on Plan Assets	(63.00)	(53.00)	(34.00)	(36.00)	(37.00)	(33.00)	(39.60)	(39.00)	(47.00)	(44.00)	(51.00)
Other Postretirement Benefits Expense (I	102.00	(21.00)	(59.00)	(75.00)	(111.00)	(146.00)	(282.00)	(372.00)	(578.00)	(90.00)	18.00
Pension Funded Status											
Fair Value of Plan Assets	21,294.00	19,592.00	20,239.00	23,147.00	21,266.00	23,542.00	25,905.00	27,075.00	17,736.00	17,487.00	16,644.00
Actual Return (Loss) on Plan Assets	1,865.00	166.00	1,632.00	2,816.00	(873.00)	3,633.00	--	--	--	--	--
Employer Contribution	493.00	1,716.00	1,360.00	1,398.00	838.00	385.00	197.00	451.00	156.00	154.00	267.00
Benefits Paid	(1,163.00)	(866.00)	(998.00)	(932.00)	(977.00)	(978.00)	(817.00)	(886.00)	(816.00)	(791.00)	(844.00)
Projected Benefit Obligation	28,852.00	25,482.00	26,687.00	28,804.00	26,373.00	28,945.00	30,307.00	28,807.00	18,917.00	18,048.00	17,144.00
Over(Under) Funded Pension	(7,558.00)	(5,890.00)	(6,448.00)	(5,657.00)	(5,107.00)	(5,403.00)	(4,402.00)	(1,732.00)	(1,181.00)	(561.00)	(500.00)
Accumulated Benefit Obligation	--	--	--	--	--	--	--	--	--	--	--
Pension Funding Ratio	73.80	76.89	75.84	80.36	80.64	81.33	85.48	93.99	93.76	96.89	97.08
Other Postretirement Funded Status											
Fair Value of Plan Assets	762.00	622.00	458.00	494.00	469.00	519.00	588.00	753.00	647.00	636.00	736.00
Actual Return (Loss) on Plan Assets	45.00	(3.00)	44.00	39.00	(22.00)	50.00	--	--	--	--	--
Employer Contribution	210.00	84.00	16.00	183.00	145.00	137.00	113.00	145.00	65.00	--	-
Benefits Paid	(309.00)	(300.00)	(282.00)	(280.00)	(249.00)	(221.00)	--	--	--	--	--
Projected Benefit Obligation	3,168.00	2,463.00	2,254.00	2,028.00	1,870.00	1,667.00	1,238.00	995.00	410.00	450.00	486.00
Over(Under) Funded Post Ret Benefits	(2,406.00)	(1,841.00)	(1,796.00)	(1,534.00)	(1,401.00)	(1,148.00)	(650.00)	(242.00)	237.00	186.00	250.00
Other Post-Retirement Funding Ratio	24.05	25.25	20.32	24.36	25.08	31.13	47.50	75.68	157.80	141.33	151.44
Actuarial Assumptions											
Pension											
Expected Return on Plan Assets	7.41	8.30	7.07	8.00	7.50	7.20	7.00	6.80	6.30	7.50	8.00
Discount Rate used on Plan Liabilities	3.74	4.50	3.78	3.80	4.40	3.30	2.60	2.90	5.40	5.40	5.40
Rate of Compensation Increase	2.76	2.80	2.74	2.80	2.80	-	-	--	-	-	-
Other Postretirement Benefits											
Expected Return on Plan Assets	8.50	8.30	8.00	8.00	7.50	7.30	7.00	6.80	6.30	7.50	8.00
Discount Rate used on Plan Liabilities	4.20	4.50	4.20	3.70	4.30	3.20	2.50	2.90	5.50	5.40	5.50
Health Care Cost Trend Projected(next y	7.00	--	--	--	--	--	--	--	--	--	--
Pension Plan Asset Allocation											
Fair Value of Plan Assets	21,294.00	19,592.00	20,239.00	23,147.00	21,266.00	23,542.00	25,905.00	27,075.00	17,736.00	17,487.00	16,644.00
Asset Category - Equities %	41.23	40.20	40.10	37.50	31.30	31.80	28.40	20.00	30.00	30.00	12.87
Asset Category - Debt %	34.52	35.00	34.90	39.60	47.10	48.70	50.20	60.00	60.00	50.00	50.03
Asset Category - Real Estate %	-	-	-	-	-	-	-	-	-	-	-
Asset Category - Company Stock %	-	-	-	-	-	-	-	-	-	-	-
Asset Category - Cash %	5.84	3.60	5.30	4.60	3.40	2.50	4.90	5.00	5.00	5.00	5.06
Asset Category - Other %	18.41	21.20	19.70	18.30	18.20	17.00	16.60	12.50	5.00	15.00	32.03
Expected Pension Payments											
Year 1	1,408.00	1,476.00	2,002.00	1,753.00	1,908.00	2,021.00	1,637.00	1,680.00	1,346.00	1,381.00	1,255.00
Year 2	1,364.00	2,124.00	1,519.00	1,573.00	1,582.00	1,560.00	1,532.00	1,527.00	1,312.00	1,268.00	1,224.00
Year 3	1,439.00	1,462.00	1,400.00	1,600.00	1,552.00	1,527.00	1,523.00	1,523.00	1,292.00	1,265.00	1,228.00
Year 4	1,540.00	1,416.00	1,421.00	1,575.00	1,518.00	1,522.00	1,521.00	1,481.00	1,280.00	1,259.00	1,210.00
Year 5	1,462.00	1,443.00	1,398.00	1,556.00	1,508.00	1,506.00	1,479.00	1,455.00	1,277.00	1,244.00	1,207.00
Beyond Year 5	7,546.00	6,988.00	6,761.00	7,479.00	7,350.00	7,186.00	7,135.00	7,032.00	6,287.00	6,077.00	5,827.00
Expected Postretirement Benefits											
Year 1	261.00	198.00	186.00	173.00	166.00	153.00	97.00	78.00	42.00	43.00	44.00
Year 2	211.00	205.00	196.00	179.00	171.00	137.00	94.00	73.00	43.00	45.00	47.00
Year 3	216.00	208.00	198.00	181.00	171.00	137.00	92.00	69.00	44.00	46.00	49.00
Year 4	220.00	208.00	197.00	179.00	168.00	136.00	89.00	66.00	44.00	47.00	50.00
Year 5	222.00	207.00	196.00	173.00	165.00	134.00	86.00	68.00	43.00	47.00	50.00
Beyond Year 5	1,146.00	1,001.00	919.00	802.00	777.00	642.00	430.00	359.00	192.00	218.00	245.00

Ticker:	PFE US EQUITY	Sort	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

[illegible]